Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory ...

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory ...

FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom’s Citizen Petition filed on December 11, 2024 and communicated the Agency’s intention to…

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032 - Phathom Pharmaceuticals (NASDAQ:PHAT)

FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom's Citizen Petition filed on December 11, 2024 and communicated the Agency's intention to correct the Orange Book to recognize the proper 10 years of New Chemical Entity exclusivity for VOQUEZNA® (vonoprazan) tablets, extending through May 3, 2032. About Phathom Pha…

Phathom Soars 95% on FDA Exclusivity for VOQUEZNA - Wall Street Pit

Phathom Pharmaceuticals Inc. (PHAT) stock soared 95% to $9.17, with an intraday high of $12.32, after the FDA approved its Citizen Petition, granting 10 years of New Chemical Entity exclusivity for VOQUEZNA® (vonoprazan) tablets until May 3, 2032. VOQUEZNA, a first-in-class potassium-competitive acid blocker, is marketed for heartburn relief in…

#Phathom Pharmaceuticals? VOQUEZNA Pioneering a New Era in Erosive GERD Treatment with Decade-Long Exclusivity and R...

Gastroesophageal reflux disease (GERD) is a chronic condition characterized by the backflow of stomach contents into the esophagus, causing symptoms such as heartburn, chest pain, and regurgitation. Among its various forms, Erosive GERD (EGD), which leads to inflammation and damage of the esophageal lining, poses significant treatment challenges. The introduction of innovative therapeutic options is essential for effective management of this pre…